Skip to main content

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma J2N-MC-JZNX

Status: Open to Enrollment
Email Us To Enroll

Study Details

View study details on clinicaltrials.gov.

Locations

  • Sunnyvale
  • Palo Alto

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

The main purpose of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The study is expected to last approximately 3 years.

Roozbeh Mohajer
Roozbeh Mohajer
Principal investigator
View Profile

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?